10 results about "Nucleic acid analogue" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to a DNA tetrahedron capable of carrying oligonucleotides and nucleic acid analogues as well as a preparation method and application of the DNA tetrahedron. The method comprises the following steps: cutting off one single-chain DNA in classical tetrahedral framework nucleic acid to form three short-chain DNAs, and self-assembling six single-chain DNAs again to form a DNA tetrahedron to obtain ORT; according to the invention, the mismatching and self-matching phenomena of tFNA are improved, the yield of tFNA is improved, and the tFNA has good structural stability, high bioavailability and excellent biocompatibility; the ORT prepared by the invention can be used as a drug carrier for loading nucleic acid and nucleic acid analogues, protein drugs or small molecule drugs, and the application of the ORT in the aspects of drug delivery, gene therapy, biosensing and the like is promoted.

The present invention relates to capture oligonucleotides, compositions or kits and methods for nucleic acid amplification. Specifically, the capture oligonucleotide comprises a universal sequence (U3s) and a binding capture sequence (1s) from the 5'end to the 3 'end; wherein (1) the binding capture sequence (1s) is at least partially identical to the 5'terminal sequence of the target molecule, and (2) the capture oligonucleotide further comprises a nucleic acid extension blocking modification located at the 3 'terminal of the binding capture sequence (1s), optionally, (3) the 3' terminal of the binding capture sequence (1s) has a nucleic acid analogue modification. The invention also provides a composition or a kit, a detection system and a method for nucleic acid amplification detection. The product and the method provided by the invention can realize nucleic acid detection with good specificity and high sensitivity.

The present invention is a nucleic acid delivery structure for use in the treatment of hematopoietic tumors, characterized by having an association structure in which a nucleic acid analogue represented by formula (1) and a nucleic acid to be delivered comprising microRNA that regulates an oncogene KRAS network are associated by electrostatic interaction. L-(S2) s-H-(S1) t-N (1) (wherein N represents a cationic artificial nucleic acid, H represents a hydrophilic polymer, S1 represents a spacer 1, S2 represents a spacer 2, and L represents a ligand; n has a constituent unit in which a base is bonded to a hexose selected from ribose and deoxyribose, a linking structure for linking the two constituent units, and a skeleton structure comprising a cationic group; the cationic artificial nucleic acid can be associated by electrostatic interaction between the phosphate group of the nucleic acid to be delivered and the cationic group. ).

Provided are a capture oligonucleotide, composition or kit for nucleic acid amplification, and a method. Specifically, the capture oligonucleotide comprises, from the 5' end to the 3' end, a universal sequence (3s) and a binding capture sequence (1s); wherein (1), the binding capture sequence (1s) is at least partially identical to the 5' end sequence of a target molecule or the binding capture sequence (1s) is at least partially identical to the 3' end sequence of a specific modification site on the target molecule; (2), the capture oligonucleotide further comprises a nucleic acid extension-blocking modification located at the 3' end of the binding capture sequence (1s); and optionally (3), the 3' end of the binding capture sequence (1s) has a nucleic acid analogue modification. Also provided are a composition or kit used for nucleic acid amplification detection, a detection system, and a method. The product and method can achieve nucleic acid detection with good specificity and high sensitivity.

To provide lipid compounds that can be used in combination with other lipid components such as neutral lipids, cholesterol, and polymer-conjugated lipids, to form lipid nanoparticles for delivering therapeutic agents (for example, nucleic acid molecules including nucleic acid mimetics such as locked nucleic acids (LNA), peptide nucleic acids (PNA), and morpholinos), both in vitro and in vivo, for therapeutic or prophylactic purposes including vaccination.SOLUTION: The present invention relates to a compound of a formula (I), or a pharmaceutically acceptable salt, a prodrug, or stereoisomer thereof.SELECTED DRAWING: None

Disclosed herein are methods to treat a neurodegenerative disease comprising administering to a subject with a neurodegenerative disease a therapeutically effective amount of a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease. Also disclosed are methods to inhibit protein aggregation in a cell comprising contacting the cell with a composition comprising a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease. Additionally disclosed are compositions comprising a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease.

An affinity reagent for analysing a biological sample includes a backbone, and a barcode oligonucleotide attached to the backbone. The backbone includes a first nucleic acid analogue. The backbone is configured to specifically bind to a target analyte by a complex structure thereof. The barcode oligonucleotide includes a second nucleic acid analogue.

The invention provides a nucleic acid compound purification method, a nucleic acid compound purification kit and application. The nucleic acid compound comprises a polynucleotide fragment and a protein combined on the polynucleotide fragment, or the nucleic acid compound is a polynucleotide fragment of which at least part of nucleotide is modified so as to lose the complementary pairing capability of nucleic acid or nucleic acid analogues. Immobilizing a nucleic acid or a nucleic acid analogue which contains a protein binding sequence on the polynucleotide fragment or a nucleotide which is complementary to the nucleotide before the modified nucleotide is modified to obtain a solid phase capture element; and S2, incubating the nucleic acid compound to be purified with the solid phase capture element, and capturing and removing polynucleotide fragments which are not self-bonded with eggs or are not successfully modified by the solid phase capture element through base complementation to obtain the purified nucleic acid compound. The purity of the linker compound purified through sequence complementation is purer than that of the compound which is not purified through the purification method, and a library constructed by taking the linker compound as the raw material can obtain a better sequencing effect.

The present invention provides an affinity reagent (102) for analyzing a biological sample. The affinity reagent (102) comprises a backbone (106) and a barcode oligonucleotide (108) attached to the backbone (106). The backbone (106) consists essentially of nucleic acid analogs. The backbone (106) is configured to specifically bind to a target analyte (114) by its complex structure. The barcode oligonucleotides (108) consist essentially of nucleic acid analogs. In another aspect, there is provided a marker (100, 206) comprising an affinity reagent (102) and a marker (104, 202). Furthermore, a method for analyzing a biological sample having a marker (100, 206) is provided.

The present disclosure relates to a structure for nucleic acid delivery, said structure being characterized by having an association structure in which a nucleic acid analog represented by formula (1) and a nucleic acid to be delivered are associated by electrostatic interaction. (In the formula: N represents a cationic artificial nucleic acid including constituent units in which a base is bonded to a ring structure selected from ribose, deoxyribose, and morpholine, and a linking structure that has a cationic group and links two constituent units; H represents a hydrophilic polymer; S1 represents a spacer 1; S2 represents a spacer 2; L represents a ligand selected from C5 or lower saccharides and derivatives thereof, alcohols, and carboxylic acids; s represents 0 or 1; t represents 0 or 1; and the cationic artificial nucleic acid may be associated by electrostatic interaction between the cationic group and a phosphate group of the nucleic acid to be delivered).